APA (7th ed.) Citation

Shepard, G., Arrowsmith, E. R., Murphy, P., Barton, J. H., Peyton, J. D., Mainwaring, M., . . . Bendell, J. C. (2017). A Phase II Study with Lead‐In Safety Cohort of 5‐Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2‐Positive Esophagogastric Adenocarcinomas. The oncologist (Dayton, Ohio), 22(10), 1152-e98. https://doi.org/10.1634/theoncologist.2017-0186

Chicago Style (17th ed.) Citation

Shepard, Gregg, Edward R. Arrowsmith, Patrick Murphy, John H. Barton, James D. Peyton, Mark Mainwaring, Laura Blakely, Noel A. Maun, and Johanna C. Bendell. "A Phase II Study with Lead‐In Safety Cohort of 5‐Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2‐Positive Esophagogastric Adenocarcinomas." The Oncologist (Dayton, Ohio) 22, no. 10 (2017): 1152-e98. https://doi.org/10.1634/theoncologist.2017-0186.

MLA (9th ed.) Citation

Shepard, Gregg, et al. "A Phase II Study with Lead‐In Safety Cohort of 5‐Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2‐Positive Esophagogastric Adenocarcinomas." The Oncologist (Dayton, Ohio), vol. 22, no. 10, 2017, pp. 1152-e98, https://doi.org/10.1634/theoncologist.2017-0186.